@article{a9083fc7eabf46a1a23fe9e183fd5f06,
title = "Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer",
abstract = "Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.",
author = "Page, {David B.} and Harry Bear and Sangeetha Prabhakaran and Gatti-Mays, {Margaret E.} and Alexandra Thomas and Erin Cobain and Heather McArthur and Balko, {Justin M.} and Gameiro, {Sofia R.} and Rita Nanda and Gulley, {James L.} and Kevin Kalinsky and Julia White and Jennifer Litton and Chmura, {Steven J.} and Polley, {Mei Yin} and Benjamin Vincent and Cescon, {David W.} and Disis, {Mary L.} and Sparano, {Joseph A.} and Mittendorf, {Elizabeth A.} and Sylvia Adams",
note = "Funding Information: D.B.P.: Research support: BMS, Merck, Brooklyn ImmunoTherapeutics. Speakers Bureau: Genentech, Novartis. Scientific Advisory Board: BMS, Merck, Syndax, Nektar, Puma, Nanostring H.B.: Receives research support from Merck and serves on the Advisory Board for Merck. S.P.: No COI or disclosures Gatti-Mays: No COI or disclosures. A.T.: Research support (to institution): Syndax, Genentech; Stockholder: Bristol-Myers Squibb, Gilead Sciences, Johnson and Johnson, Pfizer; Consultant (DSMB) BeyondSpring Pharmaceuticals (managed by Watermark Research Partners), H.M.A.: Consulting: Merck, Spectrum Pharmaceuticals, Lilly, Amgen, Immunomedics, Pfizer, Genentech, Bristol-Myers Squibb, Genomic Health. Research Funding: Bristol-Myers Squibb, ZIOPHARM Oncology, Lilly, Merck; Travel expenses: Merck, Spectrum Pharmaceuticals, Lilly, Amgen, Puma Biotechnology, Immunomedics, Genentech, Pfizer. Expert panel: Lilly. J.M.B.: Receives research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation, has received consulting/expert witness fees from Novartis, and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer. S.R.G.: No COIs or disclosures. R. N.: Advisory Board: AstraZeneca, Athenex, Celgene, Daiichi Sankyo, Inc, Genentech, MacroGenics, Merck, Novartis, Pfizer, Puma, Syndax. DSMB:G1 Therapeutics Research Funding: AstraZeneca, Celgene, Corcept. Therapeutics, Genentech/Roche, Immuno-medics, Merck, Odonate Therapeutics, Pfizer, Seattle Genetics, J.L.G.: National Cancer Institutes has several Cooperative Research and Development Agreements (CRADAs) with various biotech and pharma agencies involved in immunotherapy. Kalinsky: Consulting: Biotheranostics, Eli-Lilly, Pfizer, Amgen, Novartis, Eisai, AstraZeneca, Odonate Therapeutics, Ipsen, Genentech. Speakers{\textquoteright} bureau: Eli-Lilly. Institutional support: Incyte, Genentech, Eli-Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zeno Pharmaceuticals, CytomX Therapeutics. Spouse: employment at Array Biopharma. J.W.: None. J.L.: Research support: Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, AstraZeneca, Medimmune. Speaker{\textquoteright}s Bureau: MedLe-arning, Physician{\textquoteright}s Education Resource, Prime Oncology, Medscape. Honoraria: Uptodate; Advisory committee: AstraZeneca, Pfizer (both uncompensated). Review panels: NCCN, ASCO, NIH PDQ. S.J.C.: Astellas (spouse), RefleXion (Consulting). M.-Y.P.: No COIs or disclosures. B.V.: Research funding: Merck, Phamacyclics, Acerta Pharma; Equity: Select Immunogenomics. D.W.C.: Honoraria (non-accredited CME) Pfizer, and Novartis. Consulting or advisory role: Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Merck, Roche/Genentech, Agendia, Puma Biotechnology and Dynamo Therapeutics. Research funding (to instituton): Merck, Roche/Genentech, GlaxoSmithKline, and Pfizer. M.L.D.: COI: grants from Epithany, Celgene, EMD Serono, Pfizer, Seattle Genetics, Silverback Therapeutics, Janssen. Stockholder in Epithany. Vendor-sponsored travel: Eli-Lilly, Novartis, Genentech, Ipsen and Amgen. J.A.S.: Receives research support: Deciphera, Inc., Prescient Therapeutics; Paid consultant: Astra Zeneca, Pfizer; Pharmaceutical sponsored research: Genentech. Mittendorf: serves on advisory boards for Merck, SELLAS Lifesciences, AstraZeneca/MedImmune, TapIm-mune, and Peregrine Pharmaceuticals, and received institutional research funding from Genentech, Astra Zeneca/MedImmune, and SELLAS Lifesciences. S.A.: Advisory Board: BMS, Merck, Genentech (all uncompensated), research funding to institution: Genentech, Merck, Amgen, Novartis, BMS, Celgene. Publisher Copyright: {\textcopyright} 2019, The Author(s).",
year = "2019",
month = dec,
day = "1",
doi = "10.1038/s41523-019-0130-x",
language = "English (US)",
volume = "5",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",
}
